Groth G - Search Results

1

[Phase II-trial of tirapazamine in combination with cisplatin and gemcitabine in patients with advanced non-small-cell-lung-cancer (NSCLC)].

Reck M, von Pawel J, Nimmermann C, Groth G, Gatzemeier U. Reck M, et al. Among authors: groth g. Pneumologie. 2004 Dec;58(12):845-9. doi: 10.1055/s-2004-830056. Pneumologie. 2004. PMID: 15597251 Clinical Trial. German.

2

Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen.

Reck M, Groth G, Buchholz E, Goetz E, Gatzemeier U, Manegold C. Reck M, et al. Among authors: groth g. Lung Cancer. 2005 Jun;48(3):409-13. doi: 10.1016/j.lungcan.2004.11.013. Epub 2005 Jan 23. Lung Cancer. 2005. PMID: 15893010 Clinical Trial.

3

Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.

Gatzemeier U, Groth G, Butts C, Van Zandwijk N, Shepherd F, Ardizzoni A, Barton C, Ghahramani P, Hirsh V. Gatzemeier U, et al. Among authors: groth g. Ann Oncol. 2004 Jan;15(1):19-27. doi: 10.1093/annonc/mdh031. Ann Oncol. 2004. PMID: 14679114 Free article. Clinical Trial.

4

Difficulties in carboplatin dosage due to different methods of serum creatinine determination.

Groth G, Gatzemeier U. Groth G, et al. Lung Cancer. 2002 Oct;38(1):97-8. doi: 10.1016/s0169-5002(02)00173-3. Lung Cancer. 2002. PMID: 12367800 No abstract available.

5

Intrapleural palliative treatment of malignant pleural effusions with mitoxantrone versus placebo (pleural tube alone).

Groth G, Gatzemeier U, Häussingen K, Heckmayr M, Magnussen H, Neuhauss R, Pavel JV. Groth G, et al. Ann Oncol. 1991 Mar;2(3):213-5. doi: 10.1093/oxfordjournals.annonc.a057908. Ann Oncol. 1991. PMID: 1710483 Free article. Clinical Trial.

6

[Therapy of rhinophyma].

Groth G, Breitbart EW. Groth G, et al. Z Hautkr. 1989 Feb 15;64(2):101-2, 105-6. Z Hautkr. 1989. PMID: 2524132 German.

7

Formation of DNA-adducts and induction of DNA-crosslinks and chromosomal aberrations by the new potent anthracycline antitumor antibiotics: morpholinodaunomycin, cyanomorpholinodaunomycin and cyanomorpholinoadriamycin.

Westendorf J, Groth G, Steinheider G, Marquardt H. Westendorf J, et al. Among authors: groth g. Cell Biol Toxicol. 1985 Jan;1(2):87-101. doi: 10.1007/BF00717794. Cell Biol Toxicol. 1985. PMID: 3917129

8

The genotoxicity of lucidin, a natural component of Rubia tinctorum L., and lucidinethylether, a component of ethanolic Rubia extracts.

Westendorf J, Poginsky B, Marquardt H, Groth G, Marquardt H. Westendorf J, et al. Among authors: groth g. Cell Biol Toxicol. 1988 Jun;4(2):225-39. doi: 10.1007/BF00119248. Cell Biol Toxicol. 1988. PMID: 3069188

9

Mechanistic aspects of DNA damage by morpholinyl and cyanomorpholinyl anthracyclines.

Westendorf J, Aydin M, Groth G, Weller O, Marquardt H. Westendorf J, et al. Among authors: groth g. Cancer Res. 1989 Oct 1;49(19):5262-6. Cancer Res. 1989. PMID: 2766295

10

Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms.

Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes HP, Menger MD, Ullrich A, Vajkoczy P. Erber R, et al. Among authors: groth g. FASEB J. 2004 Feb;18(2):338-40. doi: 10.1096/fj.03-0271fje. Epub 2003 Dec 4. FASEB J. 2004. PMID: 14657001

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

135 results

Search Page

Filters